Regulation of T cell activation and tolerance by Grail

Grail 对 T 细胞活化和耐受的调节

基本信息

项目摘要

DESCRIPTION (provided by applicant): Abstract T lymphocyte activation is tightly regulated to ensure effective elimination of invading pathogens as well as maintaining tolerance against self-tissues. On one hand, T cells are regulated by extracellular signals, especially the positive and negative costimulatory molecules on antigen-presenting cells, and on the other hand, also by delicate intracellular signal transducers and regulators. Recently, we found that T cells activated in the absence of both CD28 and ICOS costimulation became nonfunctional and nonresponsive, supporting a critical role of costimulation in T cell activation. These tolerant T cells not only were anergic with profound defects in TCR signal transduction but also completely lacked expression of effector-specific transcription factors. Interestingly, expression of Grail (gene related to anergy in lymphocytes), was only upregulated in T cells when both CD28 and ICOS signaling were absent. Grail is an E3 ubiquitin ligase whose expression was previously found to be associated with CD4 T cell anergy in vitro and in vivo. Blocking of negative costimulatory signals (B7S1, B7-H3 or PD-1) restored T cell function, associated with expression of effector-specific transcription factors and down-regulation of Grail expression. To determine the function of Grail in T cell activation and tolerance, we developed a Grail mutant mouse model. We found that Grail-deficient T cells were not dependent on CD28 and ICOS signaling in activation and effector differentiation in vitro. Our central hypothesis for the current study is that Grail molecule critically regulates T cell tolerance and function. We will first analyze the role of Grail in peripheral T cell tolerance. In addition, we will determine the mechanisms whereby Grail regulates T cell tolerance. Secondly, we will analyze the function of Grail in generation and function of natural and inducible Treg cells. Lastly, we will assess whether Grail deficiency will lead to susceptibility to autoimmune diseases and whether this is caused by defects in na¿ve and/or Treg cells. These proposed studies will greatly advance our knowledge on Grail function in peripheral tolerance and autoimmune responses. PUBLIC HEALTH RELEVANCE: T lymphocyte activation is tightly regulated to ensure effective elimination of invading pathogens as well as maintaining tolerance against self-tissues. On one hand, T cells are regulated by extracellular signals, especially the positive and negative costimulatory molecules on antigen-presenting cells, and on the other hand, also by delicate intracellular signal transducers and regulators. Our preliminary analysis of a Grail knockout mouse revealed its essential function in induction of T cell tolerance in vitro. In this project, we propose to continue our analysis on function of Grail in T cells in vitro and in vivo. These proposed studies will greatly advance our knowledge on Grail function in T cells and will provide a novel and unique insight into proper T cell regulation that governs self tolerance and immune function.
描述(由申请人提供):摘要T淋巴细胞的激活受到严格的调控,以确保有效地清除入侵的病原体,同时保持对自身组织的耐受性。T细胞一方面受细胞外信号的调节,尤其是抗原提呈细胞上的正负共刺激分子,另一方面也受微妙的细胞内信号转导和调节因子的调节。最近,我们发现在没有CD28和ICOS共刺激的情况下被激活的T细胞变得无功能和无反应,支持共刺激在T细胞激活中的关键作用。这些耐受T细胞不仅在TCR信号转导方面存在严重缺陷,而且完全缺乏效应特异性转录因子的表达。有趣的是,GRAIL(与淋巴细胞无能相关的基因)只有在CD28和ICOS信号都缺失的情况下才在T细胞中表达上调。GRAIL是一种E3泛素连接酶,其表达与体内和体外的CD4T细胞无能有关。阻断负的共刺激信号(B7S1、B7-H3或PD-1)可恢复T细胞功能,这与效应器特异性转录因子的表达和GRAIL的表达下调有关。为了确定GRAIL在T细胞活化和耐受中的作用,我们建立了GRAIL突变小鼠模型。我们发现Grail缺陷T细胞在体外的激活和效应分化过程中并不依赖于CD28和ICOS信号。我们目前研究的中心假设是,Grail分子对T细胞的耐受性和功能起着关键的调节作用。我们将首先分析GRAIL在外周T细胞耐受中的作用。此外,我们还将确定GRAIL调节T细胞耐受的机制。其次,我们将分析Grail在自然和可诱导Treg细胞的产生和功能中的作用。最后,我们将评估圣杯缺乏是否会导致自身免疫性疾病的易感性,以及这是否由NA和/或Treg细胞缺陷引起。这些拟议的研究将极大地促进我们对Grail在外周耐受和自身免疫反应中的作用的了解。 公共卫生相关性:T淋巴细胞的激活受到严格控制,以确保有效地消除入侵病原体,并保持对自身组织的耐受性。T细胞一方面受细胞外信号的调节,尤其是抗原提呈细胞上的正负共刺激分子,另一方面也受微妙的细胞内信号转导和调节因子的调节。我们对Grail基因敲除小鼠的初步分析揭示了它在体外诱导T细胞耐受中的基本功能。在本项目中,我们建议继续分析Grail在体外和体内T细胞中的功能。这些拟议的研究将极大地促进我们对T细胞中Grail功能的了解,并将为调节自身耐受和免疫功能的T细胞调节提供新的和独特的见解。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Roza Insafetdinovna Nurieva其他文献

Roza Insafetdinovna Nurieva的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Roza Insafetdinovna Nurieva', 18)}}的其他基金

Mechanism-rooted therapeutic strategies for immune-related toxicities induced by checkpoint inhibitors
检查点抑制剂引起的免疫相关毒性的基于机制的治疗策略
  • 批准号:
    10753628
  • 财政年份:
    2023
  • 资助金额:
    $ 37.73万
  • 项目类别:
Role of E3 Ubiquitin ligase RNF133 in T cell function and tolerance
E3 泛素连接酶 RNF133 在 T 细胞功能和耐受性中的作用
  • 批准号:
    10311074
  • 财政年份:
    2019
  • 资助金额:
    $ 37.73万
  • 项目类别:
Role of Cul4A in Governing Th2-Type Tolerance
Cul4A 在控制 Th2 型耐受中的作用
  • 批准号:
    10198025
  • 财政年份:
    2018
  • 资助金额:
    $ 37.73万
  • 项目类别:
Role of Cul4A in Governing Th2-Type Tolerance
Cul4A 在控制 Th2 型耐受中的作用
  • 批准号:
    9770641
  • 财政年份:
    2018
  • 资助金额:
    $ 37.73万
  • 项目类别:
Grail-targeting breaks the immune tolerance to melanoma
圣杯靶向打破了对黑色素瘤的免疫耐受
  • 批准号:
    9379209
  • 财政年份:
    2017
  • 资助金额:
    $ 37.73万
  • 项目类别:
STAT1: New regulator of inflammatory Th17 and Th2 cells
STAT1:炎症 Th17 和 Th2 细胞的新调节因子
  • 批准号:
    9112386
  • 财政年份:
    2016
  • 资助金额:
    $ 37.73万
  • 项目类别:
STAT1: New regulator of inflammatory Th17 and Th2 cells
STAT1:炎症 Th17 和 Th2 细胞的新调节因子
  • 批准号:
    9206467
  • 财政年份:
    2016
  • 资助金额:
    $ 37.73万
  • 项目类别:
Role of Grail in maintaining humoral immune tolerance
Grail 在维持体液免疫耐受中的作用
  • 批准号:
    9089880
  • 财政年份:
    2015
  • 资助金额:
    $ 37.73万
  • 项目类别:
Regulation of T cell activation and tolerance by Grail
Grail 对 T 细胞活化和耐受的调节
  • 批准号:
    8468985
  • 财政年份:
    2009
  • 资助金额:
    $ 37.73万
  • 项目类别:
Regulation of T cell activation and tolerance by Grail
Grail 对 T 细胞活化和耐受的调节
  • 批准号:
    7869435
  • 财政年份:
    2009
  • 资助金额:
    $ 37.73万
  • 项目类别:

相似国自然基金

Autoimmune diseases therapies: variations on the microbiome in rheumatoid arthritis
  • 批准号:
    31171277
  • 批准年份:
    2011
  • 资助金额:
    60.0 万元
  • 项目类别:
    面上项目

相似海外基金

Autoantibodies and antibody-secreting cells in neurological autoimmune diseases: from biology to therapy
神经性自身免疫性疾病中的自身抗体和抗体分泌细胞:从生物学到治疗
  • 批准号:
    479128
  • 财政年份:
    2023
  • 资助金额:
    $ 37.73万
  • 项目类别:
    Operating Grants
Effects of maternal immune activation on autoimmune diseases in offsprings
母体免疫激活对后代自身免疫性疾病的影响
  • 批准号:
    23H02155
  • 财政年份:
    2023
  • 资助金额:
    $ 37.73万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
IPP: AUTOIMMUNE DISEASES STATISTICAL AND CLINICAL COORDINATING CENTER (ADSCCC)
IPP:自身免疫性疾病统计和临床协调中心 (ADSCCC)
  • 批准号:
    10788032
  • 财政年份:
    2023
  • 资助金额:
    $ 37.73万
  • 项目类别:
Biomarkers of vascular endothelial dysfunction in systemic autoimmune diseases: analysis of circulating microRNAs
系统性自身免疫性疾病中血管内皮功能障碍的生物标志物:循环 microRNA 分析
  • 批准号:
    23K14742
  • 财政年份:
    2023
  • 资助金额:
    $ 37.73万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
NOVEL HUMORAL AND CELLULAR BIOMARKERS OF AUTOIMMUNE DISEASES CAUSED BY IMMUNOTHERAPY
免疫治疗引起的自身免疫性疾病的新型体液和细胞生物标志物
  • 批准号:
    10593224
  • 财政年份:
    2023
  • 资助金额:
    $ 37.73万
  • 项目类别:
Structural mechanisms of autoimmune diseases targeting cys-loop receptors
针对半胱氨酸环受体的自身免疫性疾病的结构机制
  • 批准号:
    10864719
  • 财政年份:
    2023
  • 资助金额:
    $ 37.73万
  • 项目类别:
Developing non-immunosuppressive immune-based therapeutics for targeted treatment of autoimmune diseases
开发非免疫抑制性免疫疗法来靶向治疗自身免疫性疾病
  • 批准号:
    10586562
  • 财政年份:
    2023
  • 资助金额:
    $ 37.73万
  • 项目类别:
Regulation of autoimmune diseases by PTPN22 phosphatase
PTPN22磷酸酶对自身免疫性疾病的调节
  • 批准号:
    23K06589
  • 财政年份:
    2023
  • 资助金额:
    $ 37.73万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Decipher and target GABA metabolism and GABA receptor-mediated signaling in autoimmune diseases
破译并靶向自身免疫性疾病中的 GABA 代谢和 GABA 受体介导的信号传导
  • 批准号:
    10623380
  • 财政年份:
    2023
  • 资助金额:
    $ 37.73万
  • 项目类别:
Targeting the long isoform of the prolactin receptor to treat autoimmune diseases and B-cell malignancies
靶向催乳素受体的长亚型来治疗自身免疫性疾病和 B 细胞恶性肿瘤
  • 批准号:
    10735148
  • 财政年份:
    2023
  • 资助金额:
    $ 37.73万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了